Cargando…
Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid
Failure to rapidly identify drug-resistant tuberculosis (TB) increases the risk of patient mismanagement, the amplification of drug resistance, and ongoing transmission. We generated comparative analytical data for four automated assays for the detection of TB and multidrug-resistant TB (MDR-TB): Ab...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106716/ https://www.ncbi.nlm.nih.gov/pubmed/33268535 http://dx.doi.org/10.1128/JCM.02168-20 |
_version_ | 1783689819688271872 |
---|---|
author | de Vos, Margaretha Scott, Lesley David, Anura Trollip, Andre Hoffmann, Harald Georghiou, Sophia Carmona, Sergio Ruhwald, Morten Stevens, Wendy Denkinger, Claudia M. Schumacher, Samuel G. |
author_facet | de Vos, Margaretha Scott, Lesley David, Anura Trollip, Andre Hoffmann, Harald Georghiou, Sophia Carmona, Sergio Ruhwald, Morten Stevens, Wendy Denkinger, Claudia M. Schumacher, Samuel G. |
author_sort | de Vos, Margaretha |
collection | PubMed |
description | Failure to rapidly identify drug-resistant tuberculosis (TB) increases the risk of patient mismanagement, the amplification of drug resistance, and ongoing transmission. We generated comparative analytical data for four automated assays for the detection of TB and multidrug-resistant TB (MDR-TB): Abbott RealTime MTB and MTB RIF/INH (Abbott), Hain Lifescience FluoroType MTBDR (Hain), BD Max MDR-TB (BD), and Roche cobas MTB and MTB-RIF/INH (Roche). We included Xpert MTB/RIF (Xpert) and GenoType MTBDRplus as comparators for TB and drug resistance detection, respectively. We assessed analytical sensitivity for the detection of the Mycobacterium tuberculosis complex using inactivated strains (M. tuberculosis H37Rv and M. bovis) spiked into TB-negative sputa and computed the 95% limits of detection (LOD(95)). We assessed the accuracy of rifampicin and isoniazid resistance detection using well-characterized M. tuberculosis strains with high-confidence mutations accounting for >85% of first-line resistance mechanisms globally. For H37Rv and M. bovis, we measured LOD(95) values of 3,781 and 2,926 (Xpert), 322 and 2,182 (Abbott), 826 and 4,301 (BD), 10,398 and 23,139 (Hain), and 2,416 and 2,136 (Roche) genomes/ml, respectively. Assays targeting multicopy genes or targets (Abbott, BD, and Roche) showed increased analytical sensitivity compared to Xpert. Quantification of the panel by quantitative real-time PCR prevents the determination of absolute values, and results reported here can be interpreted for comparison purposes only. All assays showed accuracy comparable to that of Genotype MTBDRplus for the detection of rifampicin and isoniazid resistance. The data from this analytical study suggest that the assays may have clinical performances similar to those of WHO-recommended molecular TB and MDR-TB assays. |
format | Online Article Text |
id | pubmed-8106716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-81067162021-05-10 Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid de Vos, Margaretha Scott, Lesley David, Anura Trollip, Andre Hoffmann, Harald Georghiou, Sophia Carmona, Sergio Ruhwald, Morten Stevens, Wendy Denkinger, Claudia M. Schumacher, Samuel G. J Clin Microbiol Mycobacteriology and Aerobic Actinomycetes Failure to rapidly identify drug-resistant tuberculosis (TB) increases the risk of patient mismanagement, the amplification of drug resistance, and ongoing transmission. We generated comparative analytical data for four automated assays for the detection of TB and multidrug-resistant TB (MDR-TB): Abbott RealTime MTB and MTB RIF/INH (Abbott), Hain Lifescience FluoroType MTBDR (Hain), BD Max MDR-TB (BD), and Roche cobas MTB and MTB-RIF/INH (Roche). We included Xpert MTB/RIF (Xpert) and GenoType MTBDRplus as comparators for TB and drug resistance detection, respectively. We assessed analytical sensitivity for the detection of the Mycobacterium tuberculosis complex using inactivated strains (M. tuberculosis H37Rv and M. bovis) spiked into TB-negative sputa and computed the 95% limits of detection (LOD(95)). We assessed the accuracy of rifampicin and isoniazid resistance detection using well-characterized M. tuberculosis strains with high-confidence mutations accounting for >85% of first-line resistance mechanisms globally. For H37Rv and M. bovis, we measured LOD(95) values of 3,781 and 2,926 (Xpert), 322 and 2,182 (Abbott), 826 and 4,301 (BD), 10,398 and 23,139 (Hain), and 2,416 and 2,136 (Roche) genomes/ml, respectively. Assays targeting multicopy genes or targets (Abbott, BD, and Roche) showed increased analytical sensitivity compared to Xpert. Quantification of the panel by quantitative real-time PCR prevents the determination of absolute values, and results reported here can be interpreted for comparison purposes only. All assays showed accuracy comparable to that of Genotype MTBDRplus for the detection of rifampicin and isoniazid resistance. The data from this analytical study suggest that the assays may have clinical performances similar to those of WHO-recommended molecular TB and MDR-TB assays. American Society for Microbiology 2021-02-18 /pmc/articles/PMC8106716/ /pubmed/33268535 http://dx.doi.org/10.1128/JCM.02168-20 Text en Copyright © 2021 de Vos et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Mycobacteriology and Aerobic Actinomycetes de Vos, Margaretha Scott, Lesley David, Anura Trollip, Andre Hoffmann, Harald Georghiou, Sophia Carmona, Sergio Ruhwald, Morten Stevens, Wendy Denkinger, Claudia M. Schumacher, Samuel G. Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title | Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title_full | Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title_fullStr | Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title_full_unstemmed | Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title_short | Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid |
title_sort | comparative analytical evaluation of four centralized platforms for the detection of mycobacterium tuberculosis complex and resistance to rifampicin and isoniazid |
topic | Mycobacteriology and Aerobic Actinomycetes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106716/ https://www.ncbi.nlm.nih.gov/pubmed/33268535 http://dx.doi.org/10.1128/JCM.02168-20 |
work_keys_str_mv | AT devosmargaretha comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT scottlesley comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT davidanura comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT trollipandre comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT hoffmannharald comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT georghiousophia comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT carmonasergio comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT ruhwaldmorten comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT stevenswendy comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT denkingerclaudiam comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid AT schumachersamuelg comparativeanalyticalevaluationoffourcentralizedplatformsforthedetectionofmycobacteriumtuberculosiscomplexandresistancetorifampicinandisoniazid |